Dianthus Therapeutics (NASDAQ:DNTH) Shares Gap Up on Analyst Upgrade

Dianthus Therapeutics, Inc. (NASDAQ:DNTH)’s stock price gapped up prior to trading on Monday after Truist Financial raised their price target on the stock from $63.00 to $110.00. The stock had previously closed at $65.20, but opened at $78.90. Truist Financial currently has a buy rating on the stock. Dianthus Therapeutics shares last traded at $80.67, with a volume of 1,905,070 shares changing hands.

A number of other brokerages have also recently commented on DNTH. Jefferies Financial Group increased their price target on shares of Dianthus Therapeutics from $66.00 to $81.00 and gave the company a “buy” rating in a research note on Monday, February 2nd. HC Wainwright boosted their price objective on shares of Dianthus Therapeutics from $40.00 to $47.00 and gave the stock a “buy” rating in a research note on Monday, November 10th. Wedbush upped their target price on shares of Dianthus Therapeutics from $46.00 to $55.00 and gave the company an “outperform” rating in a report on Wednesday, February 11th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Dianthus Therapeutics in a report on Wednesday, January 21st. Nine analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $73.50.

Key Stories Impacting Dianthus Therapeutics

Here are the key news stories impacting Dianthus Therapeutics this week:

• Positive Sentiment: Early GO decision in Phase 3 CAPTIVATE — Dianthus announced an early “GO” decision following an interim responder analysis: the trial hit the GO criteria of 20 confirmed responders with fewer than 40 planned Part A completers. The company will keep the Part A dose at 300mg/2mL S.C. Q2W and plans to engage regulators about removing the 600mg/4mL option — a substantive clinical/regulatory de‑risking step for claseprubart. Article Title
• Positive Sentiment: Analyst upgrade / price-target lift — Truist raised its price target from $63 to $110 and maintained a “buy” rating, signalling increased upside expectations and likely supporting buying interest. Article Title
• Neutral Sentiment: Investor access / upcoming commentary — Dianthus hosted (and scheduled) a conference call and webcast to discuss the interim responder analysis results, which should provide additional color and could drive intraday volatility depending on management tone and Q&A. Article Title
• Neutral Sentiment: Market commentary / valuation focus — Recent write-ups evaluate DNTH after a strong run-up in the share price; these pieces can amplify debate on whether current valuation already prices the program successes. Article Title
• Negative Sentiment: Q4 earnings miss and widening loss — Dianthus reported Q4 EPS of ($1.43) vs. consensus (~$0.97 loss), missing estimates by ~$0.46; revenue was $0.57M (above an estimate of $0.40M) but the company posted extremely negative margins and ROE. The larger-than-expected loss raises near-term profitability concerns and could limit upside despite the clinical news. Article Title

Hedge Funds Weigh In On Dianthus Therapeutics

Large investors have recently modified their holdings of the stock. Patient Square Capital LP bought a new stake in shares of Dianthus Therapeutics during the 3rd quarter worth about $4,919,000. XTX Topco Ltd bought a new position in Dianthus Therapeutics in the 2nd quarter valued at about $503,000. Sio Capital Management LLC raised its holdings in Dianthus Therapeutics by 101.8% in the 2nd quarter. Sio Capital Management LLC now owns 236,070 shares of the company’s stock valued at $4,398,000 after acquiring an additional 119,073 shares during the period. Vanguard Group Inc. lifted its position in Dianthus Therapeutics by 13.6% during the third quarter. Vanguard Group Inc. now owns 1,642,198 shares of the company’s stock worth $64,620,000 after acquiring an additional 196,117 shares during the last quarter. Finally, Ensign Peak Advisors Inc acquired a new stake in Dianthus Therapeutics during the second quarter worth approximately $2,504,000. 47.53% of the stock is owned by institutional investors.

Dianthus Therapeutics Stock Up 22.7%

The business has a fifty day moving average price of $48.42 and a 200-day moving average price of $40.78. The company has a market cap of $3.46 billion, a P/E ratio of -22.99 and a beta of 1.56.

Dianthus Therapeutics (NASDAQ:DNTH) last released its quarterly earnings results on Tuesday, March 10th. The company reported ($1.43) earnings per share for the quarter, missing the consensus estimate of ($0.97) by ($0.46). Dianthus Therapeutics had a negative return on equity of 33.02% and a negative net margin of 4,106.04%.The firm had revenue of $0.57 million for the quarter, compared to analyst estimates of $0.40 million. As a group, research analysts expect that Dianthus Therapeutics, Inc. will post -2.61 earnings per share for the current year.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.